Reading Frame Correction for the Treatment of Batten Disease

阅读框架校正治疗 Batten 病

基本信息

项目摘要

CLN3 Batten disease is a fatal lysosomal storage disorder (LSD) resulting from autosomal recessive mutations in CLN3. The disease progresses from vision loss in early childhood to seizures, motor decline, cognitive disability and dementia, with a typical life expectancy of 15-30 years of age. There is no cure for CLN3 Batten and the only treatments available address some disease symptoms, but do not delay disease progression. The discovery of an effective treatment for CLN3 Batten has been hindered by a lack of understanding of the protein's function and the underlying mechanisms leading to neurodegeneration. The goal of this proposal is to test a therapeutic approach for CLN3 Batten that employs antisense oligonucleotides (ASOs) and in so doing, elucidate mechanisms of neurodegeneration in this disease that will inform research and discovery of effective treatments for Batten diseases and other LSDs. Most cases of CLN3 Batten are caused by deletion of exons 7 and 8 (CLN3Δ78), which results in an open reading frame shift and a premature termination codon. We hypothesize that using ASOs to redirect pre-mRNA splicing and correct the reading frame of CLN3Δ78 mRNA will partially restore protein function and have a therapeutic effect in CLN3 Batten disease. Our preliminary findings support our hypothesis, demonstrating that restoring the CLN3Δ78 reading frame alleviates dysfunction associated with disease in both cell and animal models. We will test our hypothesis in the proposed project with the aims to 1) compare the function of the wild type and novel CLN3 isoforms, 2) develop an approach using ASOs to increase CLN3Δex78 isoforms, 3) assess ASO treatments for CLN3 Batten disease using human cell lines as well as mouse and 4) porcine models of CLN3 Batten disease. Collectively, this study will allow us to better understand the function of the CLN3 protein and the utility of ASOs in treating CLN3 Batten disease.
CLN3Batten病是一种致命性溶酶体储存障碍(LSD),由常染色体隐性突变引起 在CLN3中。这种疾病从儿童早期的视力丧失发展到癫痫发作、运动能力下降、认知能力下降 残疾和痴呆症,典型的预期寿命为15-30岁。CLN3蝙蝠没有治愈方法 唯一可用的治疗方法可以解决一些疾病症状,但不能延缓疾病的进展。这个 由于缺乏对CLN3巴顿的了解,有效治疗CLN3巴顿的发现一直受到阻碍 蛋白质的功能和导致神经退化的潜在机制。这项提议的目标是 测试使用反义寡核苷酸(ASO)的CLN3 BATTEN的治疗方法, 阐明这种疾病的神经退行性变的机制,将为研究和发现有效的 巴顿病和其他LSD的治疗。大多数CLN3Batten病例是由外显子7缺失引起的 和8(Cln3Δ78),导致开放阅读框移位和提前终止密码子。我们 用ASOS重定向前Δ剪接并纠正CLN3基因78mR NA阅读框架的假设 将部分恢复蛋白质功能,并对CLN3巴顿病有治疗作用。我们的预赛 研究结果支持了我们的假设,表明恢复CLN3Δ78阅读框可以缓解功能障碍 在细胞和动物模型中都与疾病有关。我们将在提议的项目中检验我们的假设 为了1)比较野生型和新的CLN3亚型的功能,2)开发一种方法 利用ASO增加CLN3Δex78亚型,3)利用人类评估ASO治疗CLN3Batten病的疗效 细胞系以及小鼠和猪的CLN3BATTEN病模型。总而言之,这项研究将使我们 为了更好地了解CLN3蛋白的功能以及ASOS在治疗CLN3Batten病中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michelle L Hastings其他文献

Michelle L Hastings的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michelle L Hastings', 18)}}的其他基金

Reading Frame Correction for the Treatment of Batten Disease
阅读框架校正治疗 Batten 病
  • 批准号:
    11003569
  • 财政年份:
    2020
  • 资助金额:
    $ 58.13万
  • 项目类别:
Reading Frame Correction for the Treatment of Batten Disease
阅读框架校正治疗 Batten 病
  • 批准号:
    9917402
  • 财政年份:
    2020
  • 资助金额:
    $ 58.13万
  • 项目类别:
Reading Frame Correction for the Treatment of Batten Disease
阅读框架校正治疗 Batten 病
  • 批准号:
    10383400
  • 财政年份:
    2020
  • 资助金额:
    $ 58.13万
  • 项目类别:
Correction of Hearing and Vestibular Defects in a Mouse Model for Deafness
小鼠耳聋模型中听力和前庭缺陷的矫正
  • 批准号:
    8496335
  • 财政年份:
    2013
  • 资助金额:
    $ 58.13万
  • 项目类别:
Correction of Hearing and Vestibular Defects in a Mouse Model for Deafness
小鼠耳聋模型中听力和前庭缺陷的矫正
  • 批准号:
    8611805
  • 财政年份:
    2013
  • 资助金额:
    $ 58.13万
  • 项目类别:
Targeting SMN2 Alternative Splicing for the Treatment of Spinal Muscular Atrophy
靶向 SMN2 选择性剪接治疗脊髓性肌萎缩症
  • 批准号:
    8642676
  • 财政年份:
    2010
  • 资助金额:
    $ 58.13万
  • 项目类别:
Targeting SMN2 Alternative Splicing for the Treatment of Spinal Muscular Atrophy
靶向 SMN2 选择性剪接治疗脊髓性肌萎缩症
  • 批准号:
    8236969
  • 财政年份:
    2010
  • 资助金额:
    $ 58.13万
  • 项目类别:
Targeting SMN2 Alternative Splicing for the Treatment of Spinal Muscular Atrophy
靶向 SMN2 选择性剪接治疗脊髓性肌萎缩症
  • 批准号:
    8037088
  • 财政年份:
    2010
  • 资助金额:
    $ 58.13万
  • 项目类别:
Targeting SMN2 Alternative Splicing for the Treatment of Spinal Muscular Atrophy
靶向 SMN2 选择性剪接治疗脊髓性肌萎缩症
  • 批准号:
    7866381
  • 财政年份:
    2010
  • 资助金额:
    $ 58.13万
  • 项目类别:
Targeting SMN2 Alternative Splicing for the Treatment of Spinal Muscular Atrophy
靶向 SMN2 选择性剪接治疗脊髓性肌萎缩症
  • 批准号:
    8432873
  • 财政年份:
    2010
  • 资助金额:
    $ 58.13万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 58.13万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 58.13万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 58.13万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 58.13万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 58.13万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 58.13万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 58.13万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 58.13万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 58.13万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 58.13万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了